{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:11Z","timestamp":1786979891557,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We performed a cost-utility analysis, using prospectively gathered trial data, comparing two imaging strategies for localizing parathyroid adenomas in primary hyperparathyroidism (pHPT) to determine the most cost-effective approach. Additionally, we provide customizable open-source R-script enabling other centres to identify their optimal imaging strategy based on local diagnostic accuracy and cost data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An evaluation of the diagnostic accuracy was performed for five imaging modalities: first-line cervical ultrasound (cUS) and [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-methoxy isobutyl isonitrile-single-photon-emission-computed- tomography\/computed-tomography (MIBI SPECT\/CT), and second-line [\u00b9\u00b9C]choline positron-emitting-tomography\/CT (PET\/CT), [\u00b9\u00b9C]methionine PET\/CT, and 4 dimensional (4D)-CT. A decision-tree-model, constructed in R-studio, compared two diagnostic pathways: (1) The comparator pathway: a stepwise approach starting with cUS and MIBI SPECT\/CT escalating to one of three second-line imaging modalities if needed, and (2) use of only one second-line imaging. Costs and quality-adjusted life years (QALYs) were evaluated across pathways, and cost-utility ratios (\u20ac\/QALY) were calculated for a centre specific perspective with a 24-year time horizon based on life expectancy. In addition, to test the joint parameter uncertainty of the model, a probabilistic Monte-Carlo analysis was performed. One- and two-way sensitivity analyses were conducted to assess model robustness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>[\u00b9\u00b9C]choline PET\/CT had a total costs of \u20ac10,394 and a QALY gain of 16.66. In contrast, the current standard, cUS\u2009+\u2009MIBI SPECT\/CT with, when necessary, second-line imaging, costs \u20ac10,907 and yields 16.63 QALYs. The incremental cost-utility ratio (ICUR) for [\u00b9\u00b9C]choline PET\/CT was -\u20ac18,846\/QALY, indicating dominance with lower cost and greater effectiveness. Sensitivity analyses showed that cost-effectiveness was most sensitive to variations in costs of [\u00b9\u00b9C]choline PET\/CT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This centre-specific model supports first-line [\u00b9\u00b9C]choline PET\/CT as a cost-effective first-line strategy for localization of parathyroid adenomas, depending on [\u00b9\u00b9C]choline PET\/CT costs. Additionally, the provided cost-utility model, enables other centres to determine their optimal imaging strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07746-6","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T06:28:35Z","timestamp":1770618515000},"page":"4186-4198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of [\u00b9\u00b9C]Choline PET\/CT as first-line imaging in primary hyperparathyroidism"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8996-4353","authenticated-orcid":false,"given":"H. M.","family":"Schouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Lutterop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. H.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Noltes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"van der Hilst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"Bonnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P. A.","family":"Appelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. T.","family":"Zandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kruijff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"7746_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/B978-0-12-397166-1.00019-9","volume-title":"The Parathyroids (Third Edition)","author":"RA Wermers","year":"2015","unstructured":"Wermers RA, Clarke BL. The Parathyroids (Third Edition). In: Bilezikian JP, editor. The Parathyroids (Third Edition). 3rd ed. Elsevier Inc.; 2015. p. 297\u2013308. https:\/\/doi.org\/10.1016\/B978-0-12-397166-1.00019-9.","edition":"3"},{"key":"7746_CR2","doi-asserted-by":"publisher","unstructured":"Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. 2022;37:2315. https:\/\/doi.org\/10.1002\/JBMR.4665.","DOI":"10.1002\/JBMR.4665"},{"issue":"3","key":"7746_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/J.OTOHNS.2004.10.005","volume":"132","author":"JM Ruda","year":"2005","unstructured":"Ruda JM, Hollenbeak CS, Stack BC, John Wiley & Sons, Ltd. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132(3):359\u201372. https:\/\/doi.org\/10.1016\/J.OTOHNS.2004.10.005.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"7746_CR4","doi-asserted-by":"publisher","unstructured":"Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GEH, Marcocci C, Minisola S, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J Bone Miner Res. 2022;37:2293\u2013314. https:\/\/doi.org\/10.1002\/JBMR.4677.","DOI":"10.1002\/JBMR.4677"},{"key":"7746_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/JAMASURG.2016.2310","volume":"151","author":"SM Wilhelm","year":"2016","unstructured":"Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016;151:959\u201368. https:\/\/doi.org\/10.1001\/JAMASURG.2016.2310.","journal-title":"JAMA Surg"},{"key":"7746_CR6","doi-asserted-by":"publisher","unstructured":"Ahmadieh H, Kreidieh O, Akl EA, El-Hajj Fuleihan G. Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2020;2020. https:\/\/doi.org\/10.1002\/14651858.CD010787.PUB2\/EPDF\/ABSTRACT","DOI":"10.1002\/14651858.CD010787.PUB2\/EPDF\/ABSTRACT"},{"issue":"1","key":"7746_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/S12020-012-9746-4","volume":"43","author":"C Caldarella","year":"2013","unstructured":"Caldarella C, Treglia G, Isgr\u00f2 MA, Giordano A. Diagnostic performance of positron emission tomography using <Superscript>11<\/Superscript>C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine. 2013;43(1):78\u201383. https:\/\/doi.org\/10.1007\/S12020-012-9746-4.","journal-title":"Endocrine"},{"issue":"6","key":"7746_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/S12672-018-0347-4","volume":"9","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Lee SW, Jeong SY, Pak K, Kim K. Diagnostic performance of F-18 fluorocholine PET\/CT for parathyroid localization in hyperparathyroidism: a systematic review and meta-analysis. Horm Cancer. 2018;9(6):440\u20137. https:\/\/doi.org\/10.1007\/S12672-018-0347-4.","journal-title":"Horm Cancer"},{"key":"7746_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/RLU.0000000000000607","volume":"39","author":"M Orevi","year":"2014","unstructured":"Orevi M, Freedman N, Mishani E, Bocher M, Jacobson O, Krausz Y. Localization of parathyroid adenoma by <Superscript>11<\/Superscript>C-choline PET\/CT: preliminary results. Clin Nucl Med. 2014;39:1033\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000000607.","journal-title":"Clin Nucl Med"},{"key":"7746_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/J.SURG.2006.07.028","volume":"140","author":"SE Rodgers","year":"2006","unstructured":"Rodgers SE, Hunter GJ, Hamberg LM, Schellingerhout D, Doherty DB, Ayers GD, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery. 2006;140:932\u201341. https:\/\/doi.org\/10.1016\/J.SURG.2006.07.028.","journal-title":"Surgery"},{"key":"7746_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/S00423-017-1549-X","volume":"402","author":"ME Noltes","year":"2017","unstructured":"Noltes ME, Coester AM, van der Horst-Schrivers ANA, Dorgelo B, Jansen L, Noordzij W, et al. Localization of parathyroid adenomas using 11C-methionine pet after prior inconclusive imaging. Langenbecks Arch Surg. 2017;402:1109\u201317. https:\/\/doi.org\/10.1007\/S00423-017-1549-X.","journal-title":"Langenbecks Arch Surg"},{"key":"7746_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/S13550-021-00778-7","author":"ME Noltes","year":"2021","unstructured":"Noltes ME, Kruijff S, Jansen L, Westerlaan HE, Zandee WT, Dierckx RAJO, et al. A retrospective analysis of the diagnostic performance of 11C-choline PET\/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroidism. EJNMMI Res. 2021. https:\/\/doi.org\/10.1186\/S13550-021-00778-7.","journal-title":"EJNMMI Res"},{"key":"7746_CR13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/J.SURG.2011.09.016","volume":"150","author":"TS Wang","year":"2011","unstructured":"Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. Surg Mosby. 2011;150:1286\u201394. https:\/\/doi.org\/10.1016\/J.SURG.2011.09.016.","journal-title":"Surg Mosby"},{"key":"7746_CR14","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/S00259-021-05334-Y","volume":"48","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2021","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, Giovanella L, Carri\u00f3 Gasset I, Hindi\u00e9 E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021;48:2801\u201322. https:\/\/doi.org\/10.1007\/S00259-021-05334-Y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7746_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2967\/JNUMED.121.262395","volume":"63","author":"C Mathey","year":"2022","unstructured":"Mathey C, Keyzer C, Blocklet D, Van Simaeys G, Trotta N, Lacroix S, et al. 18F-fluorocholine PET\/CT is more sensitive than 11C-methionine PET\/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism. J Nucl Med. 2022;63:785\u201391. https:\/\/doi.org\/10.2967\/JNUMED.121.262395.","journal-title":"J Nucl Med"},{"key":"7746_CR16","doi-asserted-by":"publisher","unstructured":"Yap A, Hope TA, Graves CE, Kluijfhout W, Shen WT, Gosnell JE, et al. A cost-utility analysis of 18F-fluorocholine\u2013positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. Surgery. 2022;171:55\u201362. https:\/\/doi.org\/10.1016\/J.SURG.2021.03.075.","DOI":"10.1016\/J.SURG.2021.03.075"},{"key":"7746_CR17","doi-asserted-by":"publisher","unstructured":"van Mossel S, Saing S, Appelman-Dijkstra N, Quak E, Schepers A, Smit F et al. Cost-effectiveness of one-stop-shop [18F]Fluorocholine PET\/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism. Eur J Nucl Med Mol Imaging [Internet]. Springer; 2024 [cited 2024 Sep 23];1\u201311. https:\/\/doi.org\/10.1007\/S00259-024-06771-1\/FIGURES\/4","DOI":"10.1007\/S00259-024-06771-1\/FIGURES\/4"},{"key":"7746_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/S41824-025-00244-W","volume":"9","author":"A Mamou","year":"2025","unstructured":"Mamou A, Chkair S, Gilly O, Maimoun L, Mamou Y, Sheppard SC, et al. Economic evaluation of [18F]fluorocholine PET\/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis. EJNMMI Rep. 2025;9:11. https:\/\/doi.org\/10.1186\/S41824-025-00244-W.","journal-title":"EJNMMI Rep"},{"key":"7746_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/S00259-023-06488-7","author":"ME Noltes","year":"2024","unstructured":"Noltes ME, Kruijff S, Appelman APA, Jansen L, Zandee WT, Links TP, et al. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/S00259-023-06488-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7746_CR20","unstructured":"Opendisdata NZA. [Internet]. [cited 2025 Mar 28]. https:\/\/opendisdata.nza.nl\/#start. Accessed 28 Mar 2025."},{"key":"7746_CR21","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1245\/S10434-012-2512-2","volume":"19","author":"CC Lubitz","year":"2012","unstructured":"Lubitz CC, Stephen AE, Hodin RA, Pandharipande P. Preoperative localization strategies for primary hyperparathyroidism: an economic analysis. Ann Surg Oncol. 2012;19:4202. https:\/\/doi.org\/10.1245\/S10434-012-2512-2.","journal-title":"Ann Surg Oncol"},{"key":"7746_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/bjs.12025","volume-title":"British Journal of Surgery [Internet]","author":"A Bergenfelz","year":"2021","unstructured":"Bergenfelz A, Van Slycke S, Makay, Brunaud L. European multicentre study on outcome of surgery for sporadic primary hyperparathyroidism. In: British Journal of Surgery [Internet], vol. 108. Oxford University Press; 2021. p. 675\u201383. https:\/\/doi.org\/10.1002\/bjs.12025. [cited 2025 Mar 28];"},{"issue":"3","key":"7746_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/SLA.0B013E318208FED9","volume":"253","author":"R Udelsman","year":"2011","unstructured":"Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253(3):585\u201391. https:\/\/doi.org\/10.1097\/SLA.0B013E318208FED9.","journal-title":"Ann Surg"},{"key":"7746_CR24","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1210\/JC.2008-2006","volume":"94","author":"E Vignali","year":"2009","unstructured":"Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2306\u201312. https:\/\/doi.org\/10.1210\/JC.2008-2006.","journal-title":"J Clin Endocrinol Metab"},{"key":"7746_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/J.JVAL.2016.01.003","volume":"19","author":"M Versteegh","year":"2016","unstructured":"Versteegh M, M. Vermeulen K, M. A. A. Evers S, de Wit GA, Prenger R, A. Stolk E. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19:343\u201352. https:\/\/doi.org\/10.1016\/J.JVAL.2016.01.003.","journal-title":"Value Health"},{"key":"7746_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/S00240-020-01238-Y","volume":"49","author":"S Tapiero","year":"2021","unstructured":"Tapiero S, Limfuco L, Bechis SK, Sur RL, Penniston KL, Nakada SY, et al. The impact of the number of lifetime stone events on quality of life: results from the North American Stone Quality of Life Consortium. Urolithiasis. 2021;49:321\u20136. https:\/\/doi.org\/10.1007\/S00240-020-01238-Y.","journal-title":"Urolithiasis"},{"key":"7746_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/S001980050210","volume":"10","author":"P Lips","year":"1999","unstructured":"Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, et al. Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO). Working party for quality of life of the European foundation for osteoporosis. Osteoporos Int [Internet] Osteoporos Int. 1999;10:150\u201360. https:\/\/doi.org\/10.1007\/S001980050210. [cited 2025 Mar 28];.","journal-title":"Osteoporos Int [Internet] Osteoporos Int"},{"key":"7746_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.JVAL.2021.08.003","volume":"25","author":"M Schurer","year":"2022","unstructured":"Schurer M, Matthijsse SM, Vossen CY, van Keep M, Horscroft J, Chapman AM, et al. Varying willingness to pay based on severity of illness: impact on health technology assessment outcomes of inpatient and outpatient drug therapies in The Netherlands. Value Health. 2022;25:91\u2013103. https:\/\/doi.org\/10.1016\/J.JVAL.2021.08.003.","journal-title":"Value Health"},{"key":"7746_CR29","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare 2024 English version. 2024;1\u201339. https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare"},{"key":"7746_CR30","unstructured":"Tarieven onderlinge dienstverlening UMCG [Internet]. 2025 [cited 2025 May 21]. https:\/\/www.umcg.nl\/documents\/d\/umcg.nl\/tarieven-onderlinge-dienstverlening-2025. Accessed 21 May 2025."},{"key":"7746_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-94735-2","volume":"15","author":"S Garnier","year":"2025","unstructured":"Garnier S, Mah\u00e9o C, Potard G, Cavarec MB, Roudaut N, Thuillier P, et al. Contribution of 18 F-fluorocholine PET-CT to the preoperative localisation of parathyroid adenoma for the treatment of primary hyperparathyroidism. Sci Rep. 2025;15:1\u20139. https:\/\/doi.org\/10.1038\/s41598-025-94735-2.","journal-title":"Sci Rep"},{"issue":"5","key":"7746_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1089\/THY.2020.0555","volume":"31","author":"R Ciappuccini","year":"2021","unstructured":"Ciappuccini R, Licaj I, Lasne-Cardon A, Babin E, De Raucourt D, Blanchard D, et al. 18F-fluorocholine positron emission tomography\/computed tomography is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: the Chocolate study. Thyroid. 2021;31(5):800. https:\/\/doi.org\/10.1089\/THY.2020.0555.","journal-title":"Thyroid"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07746-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:15Z","timestamp":1777274775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07746-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7746"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07746-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study was approved by the Central Ethics Review Board for non-WMO studies (CTc UMCG), (research registry number 11168)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients that were included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No competing interests to report. The\n                      CHEERS 2022 checklist\n                      (as presented in Table 1 of Husereau et al.,\n                      PharmacoEconomics\n                      , 2022) was used as a framework to guide the reporting of this health economic evaluation. While minor deviations from the checklist were made in certain areas (e.g., the title), the majority of items were addressed in accordance with the recommended standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}